Indegene Ltd
Indegene Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Indegene sees the market opening up with stronger demand and quality of engagements compared to 12-18 months ago. Indegene sees the challenging pharma industry environment stabilizing, with reduced uncertainty and stronger demand compared to 12-18 months ago.
From Indegene Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Indegene sees the market opening up with stronger demand and quality of engagements compared to 12-18 months ago.
- The uncertain pharma environment is stabilizing, leading to companies progressing with regular plans.
- Pharma companies are focusing on efficiency and digital initiatives, including AI, creating growth opportunities.
- The Tectonic platform has a growing pipeline with multiple paid customers and potential deal closures expected by year-end.
- Brand Activation segment has a healthy pipeline expected to convert in coming quarters, helping to offset past project deferrals.
- Headcount is expected to grow but at a lower rate than revenue growth, reflecting higher productivity.
2 more points from Indegene Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Indegene Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term EBITDA margin compression of about 1.5%.
- Recent acquisitions:
- BioPharm, a U.S.-based omnichannel marketing company, acquired in October 2025 to expand capabilities in downstream omnichannel campaign execution and scale globally.
- WARN & CO, a U.K.-based boutique consulting firm specializing in change management, transformation consulting, and digital/technology for pharma, also acquired in October 2025.
- Investments include:
- Increased marketing expenses, including the IDS 2025 event in Philadelphia.
- Higher technology costs due to infrastructure, cloud subscriptions, and GenAI related expenses.
2 more points from Indegene Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indegene Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tectonic segment has built a very promising and fast-growing pipeline with expectations to close much of it by end of December 2025 or early January 2026 due to customers' Jan-Dec planning cycles.
- Two new paying customers were converted from unpaid pilots in the current quarter, indicating expanding orderbook.
- Brand Activation segment has a healthy pipeline despite some project deferrals; significant ramp-up expected in Q3 2025 to offset degrowth from closed projects.
- Strong client pipelines across top enterprise commercial and medical segments.
2 more points from Indegene Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Indegene Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹80 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indegene Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Yatharth Hospital & Trauma Care Services Ltd (Q2 FY26)
Mature hospitals have room to increase occupancy to 75%, supporting margin and revenue growth. Key concall takeaways from Yatharth Hospital & Trauma Care…
- Rainbow Childrens Medicare Ltd (Q2 FY26)
Capital expenditures were INR 260.6 crores in the recent quarter towards expansion, enhancement, and acquisitions (Guwahati and Warangal hospitals). Key…
Arthneeti Pro · Annual
Indegene Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Indegene Ltd Q2 FY26 results?
Indegene sees the market opening up with stronger demand and quality of engagements compared to 12-18 months ago. Indegene sees the challenging pharma industry environment stabilizing, with reduced uncertainty and stronger demand compared to 12-18 months ago.
What is Indegene Ltd share price analysis?
Indegene Ltd currently shows a neutral. The stock trades at a P/E of 31.3 with a market cap of ₹13,016 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene Ltd planning capital expenditure?
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term EBITDA margin compression of about 1.5%.
Keep Indegene Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.